Klinikum der Universität München (LMU Klinikum)

Risk of pelvic metastasis and significance of pelvic lymphadenectomy in patients with node-positive vulvar cancer - results of the AGO-VOP.2/QS vulva study (2022) Jaeger A, Hampl M, Zu Eulenburg C, Prieske K, Hambrecht J, Fuerst S, Klapdor R, et al. Conference contribution Re-Training of Convolutional Neural Networks for Glottis Segmentation in Endoscopic High-Speed Videos (2022) Döllinger M, Schraut T, Henrich LA, Chhetri D, Echternach M, Johnson AM, Kunduk M, et al. Journal article ExacTrac Dynamic workflow evaluation: Combined surface optical/thermal imaging and X-ray positioning (2022) Da Silva Mendes V, Reiner M, Huang L, Reitz D, Straub K, Corradini S, Niyazi M, et al. Journal article Advanced Breast Cancer: AGO Recommendations 2022 – Focus on ABC6 Consensus (2022) Untch M, Fasching P, Haidinger R, Harbeck N, Jackisch C, Lüftner D, Müller V, et al. Journal article, Review article AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022 (2022) Banys-Paluchowski M, Thill M, Kuhn T, Ditsch N, Heil J, Woeckel A, Fallenberg E, et al. Journal article CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models (2022) Seif M, Kakoschke TK, Ebel F, Bellet MM, Trinks N, Renga G, Pariano M, et al. Journal article The influence of gastric atrophy on Helicobacter pylori antibiotics resistance in therapy-naïve patients (2022) Goni E, Tammer I, Schütte K, Thon C, Jechorek D, Mahajan UM, Vasapolli R, et al. Journal article Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium (2022) Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, et al. Journal article Heterogeneity and function of conventional dendritic cells from early to adult life (2022) Schraml B, Papaioannou N, Shakiba R, Ravi K, Kuentzel V, Salei N, Lehman CH, et al. Conference contribution HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022) Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution